Bone destruction in multiple myeloma: pathogenesis and model as basis for therapeutic targeting of bone substance defects by etiology-based bone substitute material ((09) B01)

项目B1的目的是：1)增加对无症状骨髓瘤发展为症状性骨髓瘤以及与骨髓瘤骨病的发展有关的复发性骨髓瘤的了解，作为进一步开发骨替代材料的基础。2)确定将从使用此类材料的治疗中受益的患者。3)在骨髓瘤细胞系和原代骨髓瘤细胞上对所开发的材料进行体外测试，以指导材料的开发(特别是关于化合物的释放，例如Bortezomib、抗BCMA/-skerostin抗体、BMP-6)以及使用CRISPR/Cas9进行功能验证。

Aims of project B1 are 1) to increase understanding of progression of asymptomatic myeloma to symptomatic myeloma and further to relapsed myeloma which is linked to the development of myeloma bone disease as basis for further development of bone substitute materials. 2) Identification of patients who will benefit from a therapy using such materials. 3) In vitro testing of developed materials on myeloma cell lines and primary myeloma cells to direct the material development (particularly regarding the release of compounds, e.g. bortezomib, anti-BCMA/-Sclerostin antibodies, BMP-6) as well as functional validation using CRISPR/CAS9.